OUR FOCUS

At rngen, we are dedicated to advancing healthcare through innovative therapeutic drug development to address critical health challenges. Our focus on inflammation and oxidative stress allows us to create solutions that target a variety of disease states, particularly in neurological and pulmonary areas. By rigorously conducting clinical trials, we ensure that our drug candidates meet the highest standards of safety and efficacy.

Senior and nurse in the bathroom

INNOVATION

rngen is developing groundbreaking first-in-class systems chemico-pharmacology agents that address multi-target disease states. This innovative methodology sparks a series of effects that expedite symptom relief and foster better health outcomes. Our focus on tackling complex conditions positions us to revolutionize treatment options and elevate patient care standards.

Macro close up of therapist injecting enzymes

KYC-MYELOPEROXIDASE ENZYME INHIBITOR

rngen is developing groundbreaking first-in-class systems chemico-pharmacology agents that address multi-target disease states. This innovative methodology sparks a series of effects that expedite symptom relief and foster better health outcomes. Our focus on tackling complex conditions positions us to revolutionize treatment options and elevate patient care standards.

man test the elderly man

DISEASES TREATED

Our team at rngen is developing KYC (N-acetyl-lysyl tyrosyl cysteine amide) to treat critical conditions such as Sickle Cell Disease, Multiple Sclerosis, and traumatic brain injuries, including Chronic Traumatic Encephalopathy (CTE). This innovative therapy also targets Bronchopulmonary Dysplasia, a serious lung condition in premature infants. By addressing these diverse diseases, we aim to improve patient outcomes and enhance quality of life.

elderly woman and beautiful woman smile

PATIENTS

We prioritize our commitment to patients by developing therapies for critical conditions such as Bronchopulmonary Dysplasia (BPD) and Respiratory Distress Syndrome (RDS), particularly affecting premature infants. Our efforts also target diseases like Sickle Cell Disease (SCD), which significantly impacts the African American community, as well as various heart, lung, brain, and vascular conditions. Improving lives through innovative treatments remains at the heart of our mission.